Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy

Journal of Clinical Hypertension

Volumn 10, Issue 10, 2008, Pages 761-769

  Toto, Robert D ^a   Tian, Min ^b   Fakouhi, Kaffa ^b   Champion, Annette ^b   Bacher, Peter ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE PLUS BENAZEPRIL; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LISINOPRIL; POTASSIUM; TORASEMIDE; TRANDOLAPRIL PLUS VERAPAMIL; AMLODIPINE; BENAZEPRIL; BENZAZEPINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDOLE DERIVATIVE; TRANDOLAPRIL; VERAPAMIL;

ADULT; ALBUMINURIA; ARTICLE; BRADYCARDIA; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SYSTOLIC BLOOD PRESSURE; THORAX DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE LEVEL; VASCULAR DISEASE; AGED; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ALBUMINURIA; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; TREATMENT OUTCOME; VERAPAMIL;

EID: 58949095363     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00016.x     Document Type: Article

References (25)

1. Rossing P. Diabetic nephropathy: Worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep. 2006;6:479-483.
2. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol. 2005;16(suppl 1):S30-S33.
3. Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int. 2004;66:2095-2106.
4. Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601-606.
5. Anderson S. Renal effects of converting enzyme inhibitors in hypertension and diabetes. J Cardiovasc Pharmacol. 1990;15(suppl 3):S11-S15.
6. Bakris GL, Williams M, Dworkin L, et.al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
8. Epstein M. Hypertension as a risk factor for progression of chronic renal disease. Blood Press Suppl. 1994;1:23-28.
9. Estacio RO, Jeffers BW, Gifford N, et.al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54-B64.
10. Garg J, Bakris GL. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep. 2002;4:185-190.
11. Lewis EJ, Hunsicker L, Bain R, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
13. UKPDS group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
14. Wright JT Jr, Bakris G, Greene T, et.al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288:2421-2431. Erratum in: JAMA. 2006;295:2726.
15. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002.
16. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998;54:889-896.
17. Kidney Disease Outcomes Quality Initiative clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;42(2, suppl 2):S1-S179.
18. de Zeeuw D, Ramjit D, Zhang Z, et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney Int. 2006;69:1675-1682.
19. DeMarie BK, Bakris G. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Int Med. 1990;113:987-988.
20. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;112:707-708.
21. Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004;13:155-161.
22. Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/ calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283-1289.
23. PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: A randomized double-blind trial. J Hypertens. 2002;20:729-737.
24. Boero R, Rollino C, Massara C, et.al. The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. Am J Kidney Dis. 2003;42:67-75.
25. Agodoa LY, Appel L, Bakris GL, et.al. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719-2728.